Prevention of Natural Colds by Contact Prophylaxis with Intranasal Alpha2-Interferon

New England Journal of Medicine

Volumn 314, Issue 2, 1986, Pages 71-75

  Hayden, Frederick G ^a   Albrecht, Janice K ^a   Kaiser, Donald L ^a   Gwaltney, Jack M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; DRUG ANTIBODY; PLACEBO; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADVERSE DRUG REACTION; AEROSOL; CLINICAL TRIAL; COLD; COMMON COLD; CONTROLLED STUDY; CORONAVIRUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG THERAPY; DRUG TOXICITY; DRY NOSE; EPISTAXIS; FAMILY; HUMAN; INFLUENZA; INTOXICATION; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NOSE ULCER; PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOVIRUS; THERAPY;

EID: 0022644964     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198601093140202     Document Type: Article

References (18)

1. Merigan TC, Reed SE, Hall TS, Tyrrell DAJ. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973; 1: 563–7.
2. Scott GM, Phillpotts RJ, Wallace J, Gauci CL, Greiner J, Tyrrell DAJ. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet 1982; 2: 186–8.
3. Hayden FG, Gwaltney JM Jr. Intranasal interferon α2 for prevention of rhinovirus infection and illness. J Infect Dis 1983; 148: 543–50.
4. Samo TC, Greenberg SB, Palmer JM, Couch RB, Harmon MW, Johnson PE. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J Infect Dis 1984; 150: 181–8.
5. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DAJ. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24: 713–5.
6. Farr BM, Gwaltney JM Jr. Adams KF, Hayden FG. Intranasal interferon-α2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother 1984; 26: 31–4.
7. Shope T, Schwartz S, Monto A, Albrecht J. Intranasal interferon (SCH 30500) prevention of natural viral respiratory infection. Programs and abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984:270.
8. Betts RF, Erb S, Roth F, Reichman RC, Treanor J, Beutner K, Dolin R. A field trial of intranasal interferon. Program and abstracts, 13th International Congress of Chemotherapy, Vienna, Austria, 1983; 60:13–5.
9. Douglas RM, Albrecht JK, Miles HB, et al. Intranasal interferon α2 prophylaxis of natural respiratory virus infection. J Infect Dis 1985; 151: 731–6.
10. Hayden FG, Gwaltney JM Jr, Johns ME. Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha2 in natural respiratory viral infections. Antiviral Res 1985; 5: 111–6.
11. Fox JP, Hall CE, eds. Viruses in families. Littleton, Mass.: PSG, 1980:294334.
12. Gwaltney JM Jr. Rhinoviruses. In: Evans AS, ed. Viral infection of humans: epidemiology and control. 2nd ed. New York: Plenum, 1982:491517.
13. Hayden FG. Gwaltney JM Jr. Anti-interferon antibody increases rhinovirus isolation rates from nasal wash specimens containing interferon-alpha2. Antiviral Res 1983; 3: 67–71.
14. Protzman WP, Jacobs SL, Minnicozzi M, Oden EM, Kelsey DK. A radioimmunologic technique to screen for antibodies to α-2 interferon. J Immunol Methods 1984; 75: 317–23.
15. Larson HE, Reed SE, Tyrrell DAJ. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. J Med Virol 1980; 5: 221–9.
16. Douglas RM, Miles H, Moore B, Graham N, Davies L. The use of intranasal IFN alpha2 (SCH 30500) for the prevention of natural viral respiratory infections in families. Program and abstracts, 14th International Congress of Chemotherapy, Kyoto, Japan, 1985:67.
17. Herzog C, Just M, Berger R, Havas L. Fernex M. Intranasal interferon for contact prophylaxis against common cold in families. Lancet 1983; 2: 962.
18. Hayden FG, Gwaltney JM Jr. Intranasal interferon-α2 treatment of experimental rhinoviral colds. J Infect Dis 1984; 150: 174–80.